Cytarabine
Top View
- Cytarabine Injection for Intravenous, Intrathecal and Subcutaneous Use Only
- Chapter 12: Pharmacokinetics of Chemotherapeutic Agents in Kidney Disease
- Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells
- Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
- New Zealand Data Sheet 1. Product Name Cytarabine 2
- Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: from Dose Puzzle to Pharmacogenomic Biomarkers
- Capecitabine-Induced Hand-Foot Syndrome Complicated by Pseudomonal Superinfection Resulting in Bacterial Sepsis and Death Case Report and Review of the Literature
- Initial Protocol
- DRUG NAME: Gemcitabine
- Cytarabine Injection
- DA (3+8)–Cytarabine-Daunorubicin In-Patient Regimen
- Randomized Trial of Vitamin B6 for Preventing Hand-Foot Syndrome
- Toxicity and Anti-Tumor Effects of Cytarabine and Doxorubicin on Acute Myeloid Leukemia
- Hand Foot Syndrome Associated with Standard Dose Cytarabine
- Data Sheet 1 Product Name
- Combination Effect of Antitumor Agents, Including Doxorubicin
- Randomized Trial of Intermediate-Dose Cytarabine In
- Schedule-Dependent Synergism and Antagonism Between Methotrexate